Increasing access to clinical research using an innovative mobile recruitment approach: The (MoRe) concept.
Access to research
Innovative enrollment strategies
Mobile recruitment
Recruitment barriers
Veteran research
Journal
Contemporary clinical trials communications
ISSN: 2451-8654
Titre abrégé: Contemp Clin Trials Commun
Pays: Netherlands
ID NLM: 101671157
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
16
01
2020
revised:
23
06
2020
accepted:
12
07
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
11
8
2020
Statut:
epublish
Résumé
Access to healthcare delivery programs and systems is a primary correlate to the overall health and well-being of Veterans and the general population. Participation in clinical research is a gateway to novel therapies that are intended to address current global health issues. Meeting or exceeding recruitment goals in clinical research is one of the key determinants of the timely and successful completion of a study. The travel and time burdens experienced by study participants are often considered barriers to their enrollment into clinical research. The Department of Veterans Affairs (VA) Cooperative Studies Program (CSP) established a consortium of nine VA medical centers (VAMCs) called the Network of Dedicated Enrollment Sites (NODES). The NODES program provides study site-level expertise and innovative approaches that address challenges to clinical research execution. In alignment with our mission, our program developed an approach to increase study participant access to clinical research through implementing "Mobile Recruitment (MoRe)" units. This manuscript describes the utility and challenges associated with employing this strategy to address three common barriers to clinical research participation: 1) research participant travel burden, 2) participant access to study opportunities, and 3) low participant enrollment. A plan to introduce the Mobile Recruitment (MoRe) unit as a recruitment strategy was piloted for a high-volume, observational cohort study and mega biobank in the VA health care system, the "Million Veteran Program (MVP)". MoRe is a recruitment strategy for CSP research integrating mobile technology and atypical research recruitment locations. Recruitment locations include primary or main VA hospitals and their assigned VA Community-Based Outpatient Clinics (CBOCs). Each Node site (n = 9) received components of the MoRe unit including a laptop, printer, portable cart with storage space, cooler/ice packs for specimen storage and transport. Each site's usage of these components varied based on its respective needs. Activities focused on both VA main facilities and CBOC facilities for recruitment. Seven of the nine Node sites compared the effectiveness of the MoRe unit on MVP study enrollment outcomes over three-time points: pre-intervention period, intervention period, and post-intervention period. The utilization of MoRe in the intervention period demonstrated a 36.9% increase in enrollment compared to the previous six months (pre-intervention period). There was a 2% enrollment increase at the six-month post-intervention period as compared to the intervention period. When comparing the pre-intervention period to the post-intervention period (duration of eighteen months), enrollment increased by 38.9%. Five of the seven sites experienced an increase in enrollment during the intervention and post-intervention periods. The two sites without an increase in enrollment experienced various extenuating factors. Characteristics of sites using MoRe included the ability to utilize a smaller, unconventional space, i.e. not a traditional clinical research exam space for recruitment. MoRe was utilized in hospital laboratory space, CBOCs, primary care clinics, and other subspecialty clinics that allowed recruitment activities but did not have dedicated space to offer the research teams for that purpose. This initiative successfully demonstrated the benefit of deploying the unit, proving its utility in cases in where there was a lack of space or alternative workstations for research activities. The implementation of MoRe by NODES as a recruitment strategy for MVP may be transferable to other VA clinical research studies, as well as to other healthcare settings executing similar clinical research activities.
Sections du résumé
BACKGROUND
BACKGROUND
Access to healthcare delivery programs and systems is a primary correlate to the overall health and well-being of Veterans and the general population. Participation in clinical research is a gateway to novel therapies that are intended to address current global health issues. Meeting or exceeding recruitment goals in clinical research is one of the key determinants of the timely and successful completion of a study. The travel and time burdens experienced by study participants are often considered barriers to their enrollment into clinical research. The Department of Veterans Affairs (VA) Cooperative Studies Program (CSP) established a consortium of nine VA medical centers (VAMCs) called the Network of Dedicated Enrollment Sites (NODES). The NODES program provides study site-level expertise and innovative approaches that address challenges to clinical research execution. In alignment with our mission, our program developed an approach to increase study participant access to clinical research through implementing "Mobile Recruitment (MoRe)" units. This manuscript describes the utility and challenges associated with employing this strategy to address three common barriers to clinical research participation: 1) research participant travel burden, 2) participant access to study opportunities, and 3) low participant enrollment.
METHODS
METHODS
A plan to introduce the Mobile Recruitment (MoRe) unit as a recruitment strategy was piloted for a high-volume, observational cohort study and mega biobank in the VA health care system, the "Million Veteran Program (MVP)". MoRe is a recruitment strategy for CSP research integrating mobile technology and atypical research recruitment locations. Recruitment locations include primary or main VA hospitals and their assigned VA Community-Based Outpatient Clinics (CBOCs). Each Node site (n = 9) received components of the MoRe unit including a laptop, printer, portable cart with storage space, cooler/ice packs for specimen storage and transport. Each site's usage of these components varied based on its respective needs. Activities focused on both VA main facilities and CBOC facilities for recruitment.
RESULTS
RESULTS
Seven of the nine Node sites compared the effectiveness of the MoRe unit on MVP study enrollment outcomes over three-time points: pre-intervention period, intervention period, and post-intervention period. The utilization of MoRe in the intervention period demonstrated a 36.9% increase in enrollment compared to the previous six months (pre-intervention period). There was a 2% enrollment increase at the six-month post-intervention period as compared to the intervention period. When comparing the pre-intervention period to the post-intervention period (duration of eighteen months), enrollment increased by 38.9%.
CONCLUSION
CONCLUSIONS
Five of the seven sites experienced an increase in enrollment during the intervention and post-intervention periods. The two sites without an increase in enrollment experienced various extenuating factors. Characteristics of sites using MoRe included the ability to utilize a smaller, unconventional space, i.e. not a traditional clinical research exam space for recruitment. MoRe was utilized in hospital laboratory space, CBOCs, primary care clinics, and other subspecialty clinics that allowed recruitment activities but did not have dedicated space to offer the research teams for that purpose. This initiative successfully demonstrated the benefit of deploying the unit, proving its utility in cases in where there was a lack of space or alternative workstations for research activities. The implementation of MoRe by NODES as a recruitment strategy for MVP may be transferable to other VA clinical research studies, as well as to other healthcare settings executing similar clinical research activities.
Identifiants
pubmed: 32775763
doi: 10.1016/j.conctc.2020.100623
pii: S2451-8654(20)30107-1
pii: 100623
pmc: PMC7403877
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100623Investigateurs
Terence M Keane
(TM)
Pantel S Vokonas
(PS)
Dan Darroch
(D)
James LePage
(J)
Jennifer Compton
(J)
David Leehey
(D)
Conor McBurney
(C)
Stephanie Keen
(S)
Panagiotis Kougias
(P)
Sarah Perusich
(S)
Michael E DeBakey
(ME)
Timothy Morgan
(T)
Karyn Isip
(K)
Selcuk Adabag
(S)
Marti Donaire
(M)
Debra K Johnson
(DK)
Trisha Suppes
(T)
Karen Bratcher
(K)
Ann N Roseman
(AN)
Merritt Raitt
(M)
Daniel Clegg
(D)
Jennifer Romesser
(J)
Kandi Velarde
(K)
Cicilia Velarde
(C)
Christina Nessler
(C)
Sunder Mudaliar
(S)
Murray Stein
(M)
Catherine DeLue
(C)
Références
Neurotherapeutics. 2007 Jul;4(3):537-44
pubmed: 17599719
Contemp Clin Trials. 2015 Nov;45(Pt A):41-54
pubmed: 26176884
JAMA Surg. 2014 Jun;149(6):507-13
pubmed: 24647851
J Med Internet Res. 2017 Jul 31;19(7):e274
pubmed: 28760729
Am J Med. 2010 Dec;123(12 Suppl 1):e24-31
pubmed: 21184863
Med Care. 2002 Jul;40(7):570-7
pubmed: 12142772
Contemp Clin Trials Commun. 2018 Aug 07;11:156-164
pubmed: 30112460
BMC Med Res Methodol. 2004 Apr 17;4:8
pubmed: 15090073
Oncologist. 2018 Oct;23(10):1242-1249
pubmed: 29700209
Acad Med. 2018 Sep;93(9):1271-1275
pubmed: 29697433
N Engl J Med. 2019 Nov 14;381(20):1909-1917
pubmed: 31722151
Contemp Clin Trials. 2008 Mar;29(2):241-51
pubmed: 17919993
BMC Health Serv Res. 2007 Apr 18;7:56
pubmed: 17442115
Neurology. 2008 Dec 2;71(23):1883-8
pubmed: 19047560
Contemp Clin Trials Commun. 2018 Jul 10;11:107-112
pubmed: 30035242
Cancer. 2008 Jan 15;112(2):228-42
pubmed: 18008363
Implement Sci. 2012 Apr 11;7:30
pubmed: 22494428
J Clin Epidemiol. 2016 Feb;70:214-23
pubmed: 26441289
Trials. 2006 Apr 07;7:9
pubmed: 16603070
Patient Educ Couns. 2011 Jul;84(1):33-40
pubmed: 20599337
Contemp Clin Trials Commun. 2018 Feb 03;9:172-177
pubmed: 29696240
Contemp Clin Trials. 2018 Mar;66:74-79
pubmed: 29330082
BMJ. 2011 Jun 14;342:d3662
pubmed: 21672994
Appl Clin Inform. 2018 Jan;9(1):114-121
pubmed: 29444537
Contemp Clin Trials Commun. 2017 Mar 29;6:78-84
pubmed: 29740639